This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Karo Pharma Future Growth
Future criteria checks 0/6
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth
24.2%
Revenue growth rate
n/a
Future return on equity
n/a
Analyst coverage
None
Last updated
n/a
Recent future growth updates
No updates
Recent updates
In this section we usually present revenue and earnings growth
projections based on the consensus estimates of professional
analysts to help investors understand the company’s ability to
generate profit. But as Karo Pharma has not provided enough
past data and has no analyst forecast, its future earnings
cannot be reliably calculated by extrapolating past data or
using analyst predictions.
This is quite a rare situation as 97% of companies covered by
SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
DB:KA6N - Analysts future estimates and past financials data (SEK Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
6/30/2022
3,466
-190
-2,050
507
N/A
3/31/2022
3,231
-141
-1,546
572
N/A
12/31/2021
2,961
-17
-290
533
N/A
9/30/2021
2,921
63
-464
377
N/A
6/30/2021
2,861
2
-575
340
N/A
3/31/2021
2,802
49
-350
373
N/A
12/31/2020
2,883
82
-1,365
329
N/A
9/30/2020
2,811
86
-1,410
214
N/A
6/30/2020
2,575
87
-1,561
65
N/A
3/31/2020
2,274
55
-952
5
N/A
12/31/2019
1,901
9
122
107
N/A
9/30/2019
1,715
60
107
146
N/A
6/30/2019
1,667
117
353
385
N/A
3/31/2019
1,769
650
343
368
N/A
12/31/2018
1,615
657
299
318
N/A
9/30/2018
1,391
595
252
261
N/A
6/30/2018
1,132
551
82
92
N/A
3/31/2018
785
40
31
40
N/A
12/31/2017
658
15
26
34
N/A
9/30/2017
515
141
68
72
N/A
6/30/2017
463
133
76
84
N/A
3/31/2017
404
114
-10
60
N/A
12/31/2016
347
96
-106
-36
N/A
9/30/2016
308
-20
-119
-51
N/A
6/30/2016
232
-41
-125
-62
N/A
3/31/2016
151
-60
N/A
-94
N/A
12/31/2015
69
-78
N/A
-52
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if KA6N's forecast earnings growth is above the savings rate (0.03%).
Earnings vs Market: Insufficient data to determine if KA6N's earnings are forecast to grow faster than the German market
High Growth Earnings: Insufficient data to determine if KA6N's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if KA6N's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if KA6N's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if KA6N's Return on Equity is forecast to be high in 3 years time
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2022/11/27 00:22
End of Day Share Price
2022/11/24 00:00
Earnings
2022/06/30
Annual Earnings
2021/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Karo Pharma AB (publ) is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.